nodes	percent_of_prediction	percent_of_DWPC	metapath
Penbutolol—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.526	1	CbGbCtD
Penbutolol—ORM1—saliva—acquired immunodeficiency syndrome	0.0134	0.279	CbGeAlD
Penbutolol—Ache—Nevirapine—acquired immunodeficiency syndrome	0.0128	0.0306	CcSEcCtD
Penbutolol—Ache—Delavirdine—acquired immunodeficiency syndrome	0.00902	0.0216	CcSEcCtD
Penbutolol—Throat sore—Abacavir—acquired immunodeficiency syndrome	0.00779	0.0186	CcSEcCtD
Penbutolol—Oropharyngeal discomfort—Abacavir—acquired immunodeficiency syndrome	0.00772	0.0185	CcSEcCtD
Penbutolol—Rash erythematous—Nevirapine—acquired immunodeficiency syndrome	0.00771	0.0184	CcSEcCtD
Penbutolol—Rash erythematous—Zidovudine—acquired immunodeficiency syndrome	0.00647	0.0155	CcSEcCtD
Penbutolol—Oropharyngeal pain—Abacavir—acquired immunodeficiency syndrome	0.00618	0.0148	CcSEcCtD
Penbutolol—Laryngospasm—Delavirdine—acquired immunodeficiency syndrome	0.00558	0.0133	CcSEcCtD
Penbutolol—Throat sore—Lamivudine—acquired immunodeficiency syndrome	0.00491	0.0117	CcSEcCtD
Penbutolol—Oropharyngeal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.00486	0.0116	CcSEcCtD
Penbutolol—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.0044	0.092	CbGeAlD
Penbutolol—Oropharyngeal pain—Ritonavir—acquired immunodeficiency syndrome	0.00424	0.0101	CcSEcCtD
Penbutolol—Affect lability—Nelfinavir—acquired immunodeficiency syndrome	0.00409	0.00976	CcSEcCtD
Penbutolol—Affect lability—Stavudine—acquired immunodeficiency syndrome	0.00407	0.00973	CcSEcCtD
Penbutolol—Depression—Amprenavir—acquired immunodeficiency syndrome	0.00402	0.0096	CcSEcCtD
Penbutolol—Mood swings—Nelfinavir—acquired immunodeficiency syndrome	0.00393	0.0094	CcSEcCtD
Penbutolol—Mood swings—Stavudine—acquired immunodeficiency syndrome	0.00392	0.00937	CcSEcCtD
Penbutolol—Oropharyngeal pain—Lamivudine—acquired immunodeficiency syndrome	0.00389	0.0093	CcSEcCtD
Penbutolol—Affect lability—Zidovudine—acquired immunodeficiency syndrome	0.00354	0.00846	CcSEcCtD
Penbutolol—Agranulocytosis—Didanosine—acquired immunodeficiency syndrome	0.00343	0.00819	CcSEcCtD
Penbutolol—Mood swings—Zidovudine—acquired immunodeficiency syndrome	0.00341	0.00814	CcSEcCtD
Penbutolol—Disorientation—Delavirdine—acquired immunodeficiency syndrome	0.00338	0.00808	CcSEcCtD
Penbutolol—Amnesia—Efavirenz—acquired immunodeficiency syndrome	0.00336	0.00804	CcSEcCtD
Penbutolol—Amnesia—Delavirdine—acquired immunodeficiency syndrome	0.00322	0.00769	CcSEcCtD
Penbutolol—Depression—Stavudine—acquired immunodeficiency syndrome	0.00318	0.0076	CcSEcCtD
Penbutolol—Depression—Abacavir—acquired immunodeficiency syndrome	0.00313	0.00749	CcSEcCtD
Penbutolol—Affect lability—Efavirenz—acquired immunodeficiency syndrome	0.00311	0.00743	CcSEcCtD
Penbutolol—Agranulocytosis—Nevirapine—acquired immunodeficiency syndrome	0.00308	0.00737	CcSEcCtD
Penbutolol—Sweating—Nelfinavir—acquired immunodeficiency syndrome	0.00307	0.00733	CcSEcCtD
Penbutolol—Sweating—Stavudine—acquired immunodeficiency syndrome	0.00306	0.00731	CcSEcCtD
Penbutolol—Mood swings—Efavirenz—acquired immunodeficiency syndrome	0.00299	0.00716	CcSEcCtD
Penbutolol—Affect lability—Delavirdine—acquired immunodeficiency syndrome	0.00298	0.00711	CcSEcCtD
Penbutolol—Amnesia—Ritonavir—acquired immunodeficiency syndrome	0.00298	0.00711	CcSEcCtD
Penbutolol—Alopecia—Didanosine—acquired immunodeficiency syndrome	0.00291	0.00696	CcSEcCtD
Penbutolol—Amnesia—Saquinavir—acquired immunodeficiency syndrome	0.00287	0.00685	CcSEcCtD
Penbutolol—Mood swings—Delavirdine—acquired immunodeficiency syndrome	0.00287	0.00685	CcSEcCtD
Penbutolol—Affect lability—Ritonavir—acquired immunodeficiency syndrome	0.00275	0.00658	CcSEcCtD
Penbutolol—Upper respiratory tract infection—Indinavir—acquired immunodeficiency syndrome	0.00269	0.00642	CcSEcCtD
Penbutolol—Sweating—Zidovudine—acquired immunodeficiency syndrome	0.00266	0.00635	CcSEcCtD
Penbutolol—Mood swings—Ritonavir—acquired immunodeficiency syndrome	0.00265	0.00633	CcSEcCtD
Penbutolol—Agranulocytosis—Zidovudine—acquired immunodeficiency syndrome	0.00259	0.00618	CcSEcCtD
Penbutolol—Upper respiratory tract infection—Efavirenz—acquired immunodeficiency syndrome	0.00254	0.00607	CcSEcCtD
Penbutolol—Affect lability—Lamivudine—acquired immunodeficiency syndrome	0.00253	0.00604	CcSEcCtD
Penbutolol—Alopecia—Abacavir—acquired immunodeficiency syndrome	0.00249	0.00596	CcSEcCtD
Penbutolol—Sweating—Indinavir—acquired immunodeficiency syndrome	0.00247	0.00591	CcSEcCtD
Penbutolol—Mood swings—Lamivudine—acquired immunodeficiency syndrome	0.00243	0.00581	CcSEcCtD
Penbutolol—Upper respiratory tract infection—Delavirdine—acquired immunodeficiency syndrome	0.00243	0.00581	CcSEcCtD
Penbutolol—Depression—Efavirenz—acquired immunodeficiency syndrome	0.00243	0.0058	CcSEcCtD
Penbutolol—Erectile dysfunction—Delavirdine—acquired immunodeficiency syndrome	0.00241	0.00575	CcSEcCtD
Penbutolol—Sweating—Efavirenz—acquired immunodeficiency syndrome	0.00234	0.00558	CcSEcCtD
Penbutolol—Erectile dysfunction—Ritonavir—acquired immunodeficiency syndrome	0.00223	0.00532	CcSEcCtD
Penbutolol—Fatigue—Amprenavir—acquired immunodeficiency syndrome	0.00222	0.0053	CcSEcCtD
Penbutolol—Cough—Stavudine—acquired immunodeficiency syndrome	0.00218	0.0052	CcSEcCtD
Penbutolol—Upper respiratory tract infection—Saquinavir—acquired immunodeficiency syndrome	0.00216	0.00517	CcSEcCtD
Penbutolol—Depression—Ritonavir—acquired immunodeficiency syndrome	0.00215	0.00514	CcSEcCtD
Penbutolol—Erectile dysfunction—Saquinavir—acquired immunodeficiency syndrome	0.00214	0.00512	CcSEcCtD
Penbutolol—Cough—Abacavir—acquired immunodeficiency syndrome	0.00214	0.00512	CcSEcCtD
Penbutolol—Bradycardia—Delavirdine—acquired immunodeficiency syndrome	0.00213	0.00509	CcSEcCtD
Penbutolol—ORM1—blood—acquired immunodeficiency syndrome	0.00213	0.0446	CbGeAlD
Penbutolol—Depression—Saquinavir—acquired immunodeficiency syndrome	0.00207	0.00494	CcSEcCtD
Penbutolol—Sweating—Ritonavir—acquired immunodeficiency syndrome	0.00207	0.00494	CcSEcCtD
Penbutolol—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.00206	0.00493	CcSEcCtD
Penbutolol—ORM1—bone marrow—acquired immunodeficiency syndrome	0.00206	0.0431	CbGeAlD
Penbutolol—ORM1—spinal cord—acquired immunodeficiency syndrome	0.00205	0.0429	CbGeAlD
Penbutolol—Alopecia—Indinavir—acquired immunodeficiency syndrome	0.00205	0.00489	CcSEcCtD
Penbutolol—Pain—Didanosine—acquired immunodeficiency syndrome	0.002	0.00479	CcSEcCtD
Penbutolol—Depression—Lamivudine—acquired immunodeficiency syndrome	0.00197	0.00472	CcSEcCtD
Penbutolol—Hyperhidrosis—Nelfinavir—acquired immunodeficiency syndrome	0.00197	0.00471	CcSEcCtD
Penbutolol—Hyperhidrosis—Stavudine—acquired immunodeficiency syndrome	0.00197	0.0047	CcSEcCtD
Penbutolol—Alopecia—Efavirenz—acquired immunodeficiency syndrome	0.00193	0.00462	CcSEcCtD
Penbutolol—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.00192	0.0402	CbGeAlD
Penbutolol—Sweating—Lamivudine—acquired immunodeficiency syndrome	0.0019	0.00453	CcSEcCtD
Penbutolol—Cough—Zidovudine—acquired immunodeficiency syndrome	0.00189	0.00452	CcSEcCtD
Penbutolol—ORM1—lung—acquired immunodeficiency syndrome	0.00187	0.0391	CbGeAlD
Penbutolol—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.00185	0.00443	CcSEcCtD
Penbutolol—Alopecia—Delavirdine—acquired immunodeficiency syndrome	0.00185	0.00442	CcSEcCtD
Penbutolol—Agranulocytosis—Lamivudine—acquired immunodeficiency syndrome	0.00185	0.00441	CcSEcCtD
Penbutolol—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.00185	0.00441	CcSEcCtD
Penbutolol—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00184	0.00441	CcSEcCtD
Penbutolol—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.00184	0.0044	CcSEcCtD
Penbutolol—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.00182	0.00435	CcSEcCtD
Penbutolol—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.00182	0.00434	CcSEcCtD
Penbutolol—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.00181	0.00433	CcSEcCtD
Penbutolol—Pain—Nevirapine—acquired immunodeficiency syndrome	0.0018	0.00431	CcSEcCtD
Penbutolol—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.0018	0.00429	CcSEcCtD
Penbutolol—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.00179	0.00428	CcSEcCtD
Penbutolol—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.00179	0.00427	CcSEcCtD
Penbutolol—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00176	0.0042	CcSEcCtD
Penbutolol—Cough—Indinavir—acquired immunodeficiency syndrome	0.00176	0.0042	CcSEcCtD
Penbutolol—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.00175	0.00419	CcSEcCtD
Penbutolol—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00174	0.00417	CcSEcCtD
Penbutolol—Pain—Stavudine—acquired immunodeficiency syndrome	0.00174	0.00416	CcSEcCtD
Penbutolol—ORM1—nervous system—acquired immunodeficiency syndrome	0.00173	0.0362	CbGeAlD
Penbutolol—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.00173	0.00413	CcSEcCtD
Penbutolol—Pain—Abacavir—acquired immunodeficiency syndrome	0.00171	0.00409	CcSEcCtD
Penbutolol—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.00171	0.00408	CcSEcCtD
Penbutolol—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00168	0.00402	CcSEcCtD
Penbutolol—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.00167	0.00398	CcSEcCtD
Penbutolol—ORM1—central nervous system—acquired immunodeficiency syndrome	0.00166	0.0348	CbGeAlD
Penbutolol—Cough—Efavirenz—acquired immunodeficiency syndrome	0.00166	0.00397	CcSEcCtD
Penbutolol—ADRB1—lung—acquired immunodeficiency syndrome	0.00165	0.0344	CbGeAlD
Penbutolol—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.00165	0.00393	CcSEcCtD
Penbutolol—HTR1B—nervous system—acquired immunodeficiency syndrome	0.00162	0.0339	CbGeAlD
Penbutolol—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.00161	0.00385	CcSEcCtD
Penbutolol—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00161	0.00385	CcSEcCtD
Penbutolol—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00161	0.00384	CcSEcCtD
Penbutolol—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.0016	0.00383	CcSEcCtD
Penbutolol—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.0016	0.00382	CcSEcCtD
Penbutolol—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.00159	0.0038	CcSEcCtD
Penbutolol—Cough—Delavirdine—acquired immunodeficiency syndrome	0.00159	0.0038	CcSEcCtD
Penbutolol—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.00158	0.00379	CcSEcCtD
Penbutolol—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.00158	0.00377	CcSEcCtD
Penbutolol—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.00157	0.00375	CcSEcCtD
Penbutolol—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.00156	0.0326	CbGeAlD
Penbutolol—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00156	0.00372	CcSEcCtD
Penbutolol—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.00155	0.0325	CbGeAlD
Penbutolol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00153	0.00365	CcSEcCtD
Penbutolol—ADRB1—nervous system—acquired immunodeficiency syndrome	0.00152	0.0319	CbGeAlD
Penbutolol—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00152	0.00364	CcSEcCtD
Penbutolol—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00151	0.00361	CcSEcCtD
Penbutolol—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00151	0.00361	CcSEcCtD
Penbutolol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.0015	0.00359	CcSEcCtD
Penbutolol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.00149	0.00355	CcSEcCtD
Penbutolol—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00147	0.00351	CcSEcCtD
Penbutolol—Headache—Didanosine—acquired immunodeficiency syndrome	0.00147	0.00351	CcSEcCtD
Penbutolol—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.00147	0.0307	CbGeAlD
Penbutolol—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00147	0.0035	CcSEcCtD
Penbutolol—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00146	0.0035	CcSEcCtD
Penbutolol—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00349	CcSEcCtD
Penbutolol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00145	0.00346	CcSEcCtD
Penbutolol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00144	0.00344	CcSEcCtD
Penbutolol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00144	0.00344	CcSEcCtD
Penbutolol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00144	0.00343	CcSEcCtD
Penbutolol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00142	0.00339	CcSEcCtD
Penbutolol—Cough—Saquinavir—acquired immunodeficiency syndrome	0.00141	0.00338	CcSEcCtD
Penbutolol—Pain—Indinavir—acquired immunodeficiency syndrome	0.00141	0.00336	CcSEcCtD
Penbutolol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00141	0.00336	CcSEcCtD
Penbutolol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.0014	0.00334	CcSEcCtD
Penbutolol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.0014	0.00334	CcSEcCtD
Penbutolol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00139	0.00333	CcSEcCtD
Penbutolol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00139	0.00333	CcSEcCtD
Penbutolol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00139	0.00331	CcSEcCtD
Penbutolol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00137	0.00328	CcSEcCtD
Penbutolol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00137	0.00327	CcSEcCtD
Penbutolol—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00135	0.00322	CcSEcCtD
Penbutolol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00135	0.00322	CcSEcCtD
Penbutolol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00135	0.00321	CcSEcCtD
Penbutolol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00134	0.00321	CcSEcCtD
Penbutolol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00134	0.0032	CcSEcCtD
Penbutolol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00133	0.00318	CcSEcCtD
Penbutolol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00133	0.00317	CcSEcCtD
Penbutolol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00317	CcSEcCtD
Penbutolol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00133	0.00317	CcSEcCtD
Penbutolol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00132	0.00315	CcSEcCtD
Penbutolol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00131	0.00313	CcSEcCtD
Penbutolol—HTR1A—nervous system—acquired immunodeficiency syndrome	0.00131	0.0274	CbGeAlD
Penbutolol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.0013	0.00311	CcSEcCtD
Penbutolol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.00128	0.00306	CcSEcCtD
Penbutolol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00128	0.00306	CcSEcCtD
Penbutolol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00128	0.00305	CcSEcCtD
Penbutolol—ORM1—lymph node—acquired immunodeficiency syndrome	0.00128	0.0267	CbGeAlD
Penbutolol—Headache—Stavudine—acquired immunodeficiency syndrome	0.00127	0.00305	CcSEcCtD
Penbutolol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00127	0.00304	CcSEcCtD
Penbutolol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00303	CcSEcCtD
Penbutolol—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.00126	0.0263	CbGeAlD
Penbutolol—Headache—Abacavir—acquired immunodeficiency syndrome	0.00126	0.003	CcSEcCtD
Penbutolol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00125	0.00299	CcSEcCtD
Penbutolol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00124	0.00297	CcSEcCtD
Penbutolol—HTR1B—brain—acquired immunodeficiency syndrome	0.00124	0.0259	CbGeAlD
Penbutolol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.00123	0.00293	CcSEcCtD
Penbutolol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.00293	CcSEcCtD
Penbutolol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00122	0.00292	CcSEcCtD
Penbutolol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00121	0.0029	CcSEcCtD
Penbutolol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.00121	0.00289	CcSEcCtD
Penbutolol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00121	0.00289	CcSEcCtD
Penbutolol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00121	0.00289	CcSEcCtD
Penbutolol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.0012	0.00286	CcSEcCtD
Penbutolol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00119	0.00284	CcSEcCtD
Penbutolol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.00119	0.00283	CcSEcCtD
Penbutolol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00282	CcSEcCtD
Penbutolol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00118	0.00282	CcSEcCtD
Penbutolol—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00118	0.00281	CcSEcCtD
Penbutolol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.00281	CcSEcCtD
Penbutolol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00117	0.00279	CcSEcCtD
Penbutolol—ADRB1—brain—acquired immunodeficiency syndrome	0.00117	0.0244	CbGeAlD
Penbutolol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.00116	0.00278	CcSEcCtD
Penbutolol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00114	0.00273	CcSEcCtD
Penbutolol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00114	0.00273	CcSEcCtD
Penbutolol—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00113	0.0027	CcSEcCtD
Penbutolol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.00269	CcSEcCtD
Penbutolol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00113	0.00269	CcSEcCtD
Penbutolol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00111	0.00266	CcSEcCtD
Penbutolol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.00111	0.00265	CcSEcCtD
Penbutolol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00111	0.00265	CcSEcCtD
Penbutolol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00109	0.0026	CcSEcCtD
Penbutolol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00109	0.0026	CcSEcCtD
Penbutolol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.0026	CcSEcCtD
Penbutolol—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00108	0.00258	CcSEcCtD
Penbutolol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00107	0.00255	CcSEcCtD
Penbutolol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00106	0.00254	CcSEcCtD
Penbutolol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00105	0.00251	CcSEcCtD
Penbutolol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.0025	CcSEcCtD
Penbutolol—Headache—Indinavir—acquired immunodeficiency syndrome	0.00103	0.00246	CcSEcCtD
Penbutolol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00103	0.00245	CcSEcCtD
Penbutolol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00102	0.00243	CcSEcCtD
Penbutolol—HTR1A—brain—acquired immunodeficiency syndrome	0.001	0.0209	CbGeAlD
Penbutolol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000998	0.00238	CcSEcCtD
Penbutolol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000986	0.00236	CcSEcCtD
Penbutolol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000983	0.00235	CcSEcCtD
Penbutolol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000977	0.00233	CcSEcCtD
Penbutolol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000973	0.00233	CcSEcCtD
Penbutolol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000949	0.00227	CcSEcCtD
Penbutolol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000941	0.00225	CcSEcCtD
Penbutolol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000931	0.00223	CcSEcCtD
Penbutolol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000923	0.00221	CcSEcCtD
Penbutolol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000909	0.00217	CcSEcCtD
Penbutolol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000906	0.00216	CcSEcCtD
Penbutolol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000905	0.00216	CcSEcCtD
Penbutolol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000883	0.00211	CcSEcCtD
Penbutolol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000875	0.00209	CcSEcCtD
Penbutolol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000864	0.00206	CcSEcCtD
Penbutolol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000861	0.00206	CcSEcCtD
Penbutolol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000835	0.00199	CcSEcCtD
Penbutolol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000829	0.00198	CcSEcCtD
Penbutolol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000817	0.00195	CcSEcCtD
Penbutolol—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000791	0.00189	CcSEcCtD
Penbutolol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000786	0.00188	CcSEcCtD
Penbutolol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00075	0.00179	CcSEcCtD
Penbutolol—ADRB2—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.000213	0.0286	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000168	0.0226	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000134	0.018	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000131	0.0176	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000128	0.0172	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000128	0.0172	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000102	0.0137	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000102	0.0137	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	9.99e-05	0.0134	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	9.77e-05	0.0131	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	9.22e-05	0.0124	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	8.12e-05	0.0109	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	7.95e-05	0.0106	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	7.77e-05	0.0104	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	7.77e-05	0.0104	CbGpPWpGaD
Penbutolol—ADRB2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	7.69e-05	0.0103	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	7.35e-05	0.00984	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	7.19e-05	0.00963	CbGpPWpGaD
Penbutolol—HTR1B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	7.17e-05	0.0096	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	7.03e-05	0.00941	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	7.02e-05	0.00941	CbGpPWpGaD
Penbutolol—HTR1B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	6.74e-05	0.00903	CbGpPWpGaD
Penbutolol—HTR1B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	6.74e-05	0.00903	CbGpPWpGaD
Penbutolol—HTR1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	6.65e-05	0.00891	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	6.58e-05	0.00881	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	6.3e-05	0.00844	CbGpPWpGaD
Penbutolol—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	6.25e-05	0.00838	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	6.19e-05	0.00829	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	6.05e-05	0.00811	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.92e-05	0.00793	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	5.7e-05	0.00764	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.59e-05	0.0075	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.47e-05	0.00733	CbGpPWpGaD
Penbutolol—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	5.46e-05	0.00732	CbGpPWpGaD
Penbutolol—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	5.4e-05	0.00723	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	5.36e-05	0.00718	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	5.36e-05	0.00718	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.35e-05	0.00717	CbGpPWpGaD
Penbutolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.3e-05	0.0071	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.24e-05	0.00702	CbGpPWpGaD
Penbutolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.18e-05	0.00694	CbGpPWpGaD
Penbutolol—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	5.13e-05	0.00688	CbGpPWpGaD
Penbutolol—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	5.13e-05	0.00688	CbGpPWpGaD
Penbutolol—HTR1B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	5.13e-05	0.00687	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.13e-05	0.00687	CbGpPWpGaD
Penbutolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.07e-05	0.00679	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	5.02e-05	0.00672	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.01e-05	0.00672	CbGpPWpGaD
Penbutolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.98e-05	0.00667	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.91e-05	0.00658	CbGpPWpGaD
Penbutolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.87e-05	0.00653	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.8e-05	0.00643	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	4.8e-05	0.00643	CbGpPWpGaD
Penbutolol—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.76e-05	0.00638	CbGpPWpGaD
Penbutolol—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	4.62e-05	0.00619	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.54e-05	0.00608	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.44e-05	0.00595	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.34e-05	0.00582	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.34e-05	0.00581	CbGpPWpGaD
Penbutolol—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.29e-05	0.00574	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.27e-05	0.00572	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.27e-05	0.00572	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.17e-05	0.00559	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.17e-05	0.00559	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.08e-05	0.00547	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.08e-05	0.00547	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.08e-05	0.00547	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.08e-05	0.00547	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.08e-05	0.00546	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.99e-05	0.00534	CbGpPWpGaD
Penbutolol—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.91e-05	0.00523	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.89e-05	0.00521	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.82e-05	0.00512	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.74e-05	0.00501	CbGpPWpGaD
Penbutolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.67e-05	0.00492	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.66e-05	0.0049	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.6e-05	0.00483	CbGpPWpGaD
Penbutolol—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.52e-05	0.00471	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.46e-05	0.00463	CbGpPWpGaD
Penbutolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.41e-05	0.00457	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.38e-05	0.00453	CbGpPWpGaD
Penbutolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.34e-05	0.00447	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.31e-05	0.00443	CbGpPWpGaD
Penbutolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.27e-05	0.00437	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.25e-05	0.00435	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.25e-05	0.00435	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.00435	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.18e-05	0.00426	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.18e-05	0.00426	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.18e-05	0.00425	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.17e-05	0.00425	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.11e-05	0.00416	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.11e-05	0.00416	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.11e-05	0.00416	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.11e-05	0.00416	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.1e-05	0.00416	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.1e-05	0.00415	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.04e-05	0.00407	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.03e-05	0.00406	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.96e-05	0.00397	CbGpPWpGaD
Penbutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.92e-05	0.00392	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.87e-05	0.00385	CbGpPWpGaD
Penbutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.86e-05	0.00383	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.81e-05	0.00376	CbGpPWpGaD
Penbutolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.8e-05	0.00375	CbGpPWpGaD
Penbutolol—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.8e-05	0.00375	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.75e-05	0.00368	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.47e-05	0.00331	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.46e-05	0.0033	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.45e-05	0.00329	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.42e-05	0.00324	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.36e-05	0.00317	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.35e-05	0.00315	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.35e-05	0.00315	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.31e-05	0.00309	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.31e-05	0.00309	CbGpPWpGaD
Penbutolol—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.23e-05	0.00298	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.23e-05	0.00298	CbGpPWpGaD
Penbutolol—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.18e-05	0.00292	CbGpPWpGaD
Penbutolol—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.13e-05	0.00285	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.13e-05	0.00285	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.09e-05	0.00281	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.09e-05	0.00281	CbGpPWpGaD
Penbutolol—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.05e-05	0.00275	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.96e-05	0.00263	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.95e-05	0.00262	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.92e-05	0.00257	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.91e-05	0.00256	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.88e-05	0.00251	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.88e-05	0.00251	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.88e-05	0.00251	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.87e-05	0.0025	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.84e-05	0.00246	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.84e-05	0.00246	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.83e-05	0.00246	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.83e-05	0.00246	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.8e-05	0.00241	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.8e-05	0.00241	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.79e-05	0.0024	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.79e-05	0.0024	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.77e-05	0.00238	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.76e-05	0.00235	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.76e-05	0.00235	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.75e-05	0.00235	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.73e-05	0.00232	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.00232	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.7e-05	0.00227	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.7e-05	0.00227	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.67e-05	0.00223	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.67e-05	0.00223	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.66e-05	0.00222	CbGpPWpGaD
Penbutolol—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.66e-05	0.00222	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.63e-05	0.00219	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.63e-05	0.00219	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.62e-05	0.00217	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.6e-05	0.00214	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.6e-05	0.00214	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.59e-05	0.00213	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.00212	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.57e-05	0.0021	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.45e-05	0.00195	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.44e-05	0.00192	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.4e-05	0.00187	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.00184	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.37e-05	0.00183	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.35e-05	0.0018	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.34e-05	0.00179	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.32e-05	0.00176	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.32e-05	0.00176	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.27e-05	0.0017	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.26e-05	0.00169	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.25e-05	0.00167	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.24e-05	0.00166	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.24e-05	0.00166	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.24e-05	0.00166	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.00165	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.22e-05	0.00164	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.00163	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.2e-05	0.00161	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.2e-05	0.0016	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.16e-05	0.00155	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.14e-05	0.00153	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.13e-05	0.00152	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.12e-05	0.0015	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.11e-05	0.00148	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.00146	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.05e-05	0.0014	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.02e-05	0.00137	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1e-05	0.00134	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.85e-06	0.00132	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.85e-06	0.00132	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.64e-06	0.00129	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.64e-06	0.00129	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.42e-06	0.00126	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.42e-06	0.00126	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.41e-06	0.00126	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.27e-06	0.00124	CbGpPWpGaD
Penbutolol—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.13e-06	0.00122	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.48e-06	0.00114	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.29e-06	0.00111	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.49e-06	0.001	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.38e-06	0.000989	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.33e-06	0.000982	CbGpPWpGaD
Penbutolol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.27e-06	0.000974	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.22e-06	0.000968	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.17e-06	0.00096	CbGpPWpGaD
Penbutolol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.11e-06	0.000953	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.06e-06	0.000946	CbGpPWpGaD
Penbutolol—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.96e-06	0.000932	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.75e-06	0.000905	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.6e-06	0.000885	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.6e-06	0.000885	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.46e-06	0.000866	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.46e-06	0.000865	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.32e-06	0.000846	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.9e-06	0.000656	CbGpPWpGaD
Penbutolol—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.87e-06	0.000653	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.9e-06	0.000523	CbGpPWpGaD
Penbutolol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.88e-06	0.00052	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.82e-06	0.000511	CbGpPWpGaD
Penbutolol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.8e-06	0.000509	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.73e-06	0.0005	CbGpPWpGaD
Penbutolol—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.71e-06	0.000497	CbGpPWpGaD
Penbutolol—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.88e-06	0.000386	CbGpPWpGaD
Penbutolol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.29e-06	0.000307	CbGpPWpGaD
Penbutolol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.24e-06	0.000301	CbGpPWpGaD
Penbutolol—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.19e-06	0.000294	CbGpPWpGaD
